DEATH FOLLOWING PHENYLBUTAZONE (BUTAZOLIDIN) THERAPY: REPORT OF A CASE
Authors: D A NATHAN, M L MEITUS, L CAPLAND, M LEV
Journal: Annals of Internal Medicine (1953)

Case Reports1 November 1953DEATH FOLLOWING PHENYLBUTAZONE (BUTAZOLIDIN) THERAPY: REPORT OF A CASEDAVID A. NATHAN, M.D., F.A.C.P., MARVIN L. MEITUS, M.D., LEWIS CAPLAND, M.D., MAURICE LEV, M.D.DAVID A. NATHAN, M.D., F.A.C.P.Search for more papers by this author, MARVIN L. MEITUS, M.D.Search for more papers by this author, LEWIS CAPLAND, M.D.Search for more papers by this author, MAURICE LEV, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-39-5-1096 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptVarious undesirable effects have been reported following the use of phenylbutazone (Butazolidin) in the therapy of arthritis and allied rheumatic disorders. Since the initial American clinical evaluation by Kuzell, Schaffarzick, Brown and Mankle,1the medical literature is gradually acquiring more and more case histories of heretofore undescribed reactions as well as previously experienced characteristic toxic manifestations due to this compound. First synthesized by the chemists of J. R. Geigy, S. A., of Basle, Switzerland, phenylbutazone (3, 5-dioxo-1, 2-diphenyl-4 n-butyl pyrazolidin sodium) is a synthetic derivative of pyrazol. Aminopyrine (Pyramidon) has the chemical formula 1-phenyl-2, 3-dimethyl-4-dimethylamino-5 pyrazolone, thus indicating a definite...Bibliography1. KuzellSchaffarzickBrownMankle WCRWBEA: Phenylbutazone (Butazolidin) in rheumatoid arthritis and gout, J. A. M. A. 149: 729 (June 1) 1952. CrossrefMedlineGoogle Scholar2. HemmingKuzell AWC: The pharmacologic and clinical characteristics of phenylbutazone (Butazolidin), Antibiotics and Chemotherapy 3: 6, 1953. Google Scholar3. EtessJacobson ADAS: Fatality due to agranulocytosis following use of phenylbutazone (Butazolidin), J. A. M. A. 151: 639 (Feb. 21) 1953. CrossrefMedlineGoogle Scholar4. SteinbergBohrodRoodenburg CLMGAI: Agranulocytosis following phenylbutazone (Butazolidin) therapy, J. A. M. A. 152: 33 (May 2) 1953. CrossrefMedlineGoogle Scholar5. Hemming A, Geigy Company, Inc.: Personal communication. Google Scholar6. BurnsSchulertChenkinGoldmanBrodie JJATABB: The physiological disposition of phenylbutazone (Butazolidin), a new antirheumatic agent, J. Pharmacol. and Exper. Therap. 106: 375, 1952. Google Scholar7. CharetSiegel RI: Unusual reaction following use of phenylbutazone (Butazolidin), J. A. M. A. 151: 556 (Feb. 14) 1953. CrossrefMedlineGoogle Scholar8. StephensYeomanHolbrookHillGoodin CAEEWPDFWL: Benefits and toxicity of phenylbutazone (Butazolidin) in rheumatoid arthritis, J. A. M. A. 150: 1085 (Nov. 15) 1952. CrossrefGoogle Scholar9. RoweTufftMechanickRowe ARWPGAH: Am. Pract. and Digest Treat., in press. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Miami Beach, Florida*Received for publication August 26, 1953.From the Departments of Medicine and Pathology of The Mount Sinai Hospital of Greater Miami, Miami Beach, Florida. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byButazolidine Sodium 129-18-0Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literatureGranulomas and cholestatic-hepatocellular injury associated with phenylbutazoneCytologic and Histologic Aspects of Toxically Induced Liver ReactionsREFERENCESRENAL VASCULAR CHANGES IN ANKYLOSING SPONDYLITISIrgapyrin� -Vergiftung eines Kindes mit t�dlichem Ausgang unter besonderer Ber�cksichtigung von Ver�nderungen im Elektrokardiogramm und toxikologischen UntersuchungenAcute Renal Failure Caused by PhenylbutazoneErkrankungen des EndokardA Case of Poisoning with 10 Grams of ButazolidinPhenylbutazone in rheumatoid arthritisManagement of GoutRHEUMATISM AND ARTHRITIS REVIEW OF AMERICAN AND ENGLISH LITERATURE OF RECENT YEARS (ELEVENTH RHEUMATISM REVIEW)* Part IIWILLIAM D. ROBINSON, M.D., F.A.C.P., JOSEPH J. BUNIM, M.D., F.A.C.P., WILLIAM S. CLARK, M.D., DARRELL C. CRAIN, M.D., F.A.C.P., EPHRAIM P. ENGLEMAN, M.D., F.A.C.P., DONALD C. GRAHAM, M.D., F.R.C.P. (C), MAX M. MONTGOMERY, M.D., F.A.C.P., BERNARD M. NORCROSS, M.D., F.A.C.P., CHARLES RAGAN, M.D., F.A.C.P., MARIAN W. ROPES, M.D., F.A.C.P., EDWARD F. ROSENBERG, M.D., F.A.C.P., CHARLEY J. SMYTH, M.D., F.A.C.P.Antipyretische AnalgetikaAntipyretische AnalgetikaThe Toxic Effects of Phenylbutazone (Butazolidin)Rheumatoid arthritis: A review of recent advances in our knowledge concerning pathology, diagnosis, and treatment 1 November 1953Volume 39, Issue 5Page: 1096-1103KeywordsChemistsHospital medicineRheumatic feverSodium ePublished: 1 December 2008 Issue Published: 1 November 1953 PDF downloadLoading ...